We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Field Evaluation of Quantitative G6PD Diagnostics Reviewed

By LabMedica International staff writers
Posted on 27 Sep 2017
Print article
Image: The qualitative point-of-care test CareStart G6PD RDT is a visual screening test that identifies G6PD deficient patients using whole blood sample. Panel A, no color change for sample with deficient G6PD enzymatic activity; Panel B, distinct purple color for sample with normal G6PD enzymatic activity (Photo courtesy of Access Bio).
Image: The qualitative point-of-care test CareStart G6PD RDT is a visual screening test that identifies G6PD deficient patients using whole blood sample. Panel A, no color change for sample with deficient G6PD enzymatic activity; Panel B, distinct purple color for sample with normal G6PD enzymatic activity (Photo courtesy of Access Bio).
Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common enzymopathy with at least 400 million individuals affected worldwide. More than 185 clinically relevant variants of G6PDd have been reported with a spectrum of associated enzyme deficiencies.

The presence of G6PDd in patients with Plasmodium vivax infection results in significant challenges to achieving radical cure. The 8-aminoquinolone compounds are the only class of anti-malarial drugs currently available to eliminate the dormant hypnozoites liver stages of P. vivax are and these cause hemolysis in G6PDd individuals.

Scientists at the Charles Darwin University (Sydney, Australia) and their colleagues reviewed the methods for the field evaluation of quantitative G6PD diagnostics. G6PD enzyme activity and its degradation is temperature dependent, hence whole EDTA blood should not be stored at room temperature. Freezing samples and maintaining a respective cold chain in a field setting is demanding and often impossible. Whole blood samples can be stored at 4–8 °C for later analysis; however the duration at which samples can be stored and reliably assayed at a later time point is unknown. Field evaluation is based on the comparison of paired samples, including one sample tested by the new assay at point of care and one sample tested by the gold-standard reference method, UV spectrophotometry in an established laboratory.

In one study the G6PD activity of paired samples collected from venous and capillary sampling were similar when measured by spectrophotometry, the medians were 7.51 and 7.61 U/gHb, respectively. Similarly, an evaluation of qualitative tests by fluorescent spot test (FST) and Carestart G6PD RDT showed 100% concordance between paired capillary and venous samples. ACCESS BIO has recently developed a Biosensor, a quantitative handheld device that measures G6PD activity based on the electrochemical properties of G6PD in blood samples.

The WST8/1-methoxy PMS test is a robust and cost effective alternative to estimate G6PD activity that can be performed on dried blood spots and whole blood samples. The WST8/1 test is based on the formation of an orange formazan dye generated by G6PD enzyme activity and facilitated by the 1-methoxy PMS as an electron carrier. The assay has been adapted for quantitative batch testing in a 96 well microplate and can be read by an enzyme-linked immunosorbent assay (ELISA) reader.

The authors concluded that their review presented a number of recommendations to facilitate standardized evaluation of quantitative G6PD activity test assays. Standardized evaluation studies are necessary to provide a comparable basis for subsequent pooled analyses. As novel quantitative G6PD diagnostics become available their potential to provide robust quantitative G6PD results suitable for field deployment needs to be assessed. The most recent generation of instruments contain an integrated temperature correction factor and hemoglobin measurement and G6PD activity is displayed normalized as U/gHb. The study was published on September 11, 2017, in the Malaria Journal.

Related Links:
Charles Darwin University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The AI-based method can more accurately detect antibiotic resistance in deadly bacteria such as tuberculosis and staph (Photo courtesy of Adobe Stock)

New AI-Based Method Improves Diagnosis of Drug-Resistant Infections

Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.